Karol H Kerr, MD

Karol H Kerr, MD
Appointed 09/01/11
4300 Upstate University Hospital - Downtown Campus
750 East Adams Street
Syracuse, NY 13210

315 464-8668

Current Appointments

Hospital Campus

  • Downtown

Clinical Section Affiliations

  • Pediatrics: Hematology and Oncology
  • Upstate Cancer Center: Pediatrics

Clinic/Unit

Education & Fellowships

  • Fellowship: Stanford University Hospital, 1994, Pediatric Heme/Onc
  • Residency: Kaiser Foundation Hospital, 1991, Chief Resident - Pediatrics
  • Residency: Kaiser Foundation Hospital, 1990, Pediatrics
  • MD: University of Alabama at Birmingham, 1987
  • BS: University of Alabama at Birmingham, 1981, microbiology

Clinical Trials

  • (CA180372) A Phase II Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    Read more
  • (SCUSF 0901) A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor
    Read more
  • 4941L: National Wilms Tumor Late Effects Study
    Read more
  • A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens
    Read more
  • A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
    Read more
  • A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
    Read more
  • A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
    Read more
  • A Children's Oncology Group Protocols for Collecting and Banking Pediatric Brain Tumor Research Specimens
    Read more
  • A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
    Read more
  • A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas
    Read more
  • A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
    Read more
  • A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
    Read more
  • A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chermotherapy in Initial Treatment of non-metastatic Ewing Sarcoma
    Read more
  • A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition
    Read more
  • A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma
    Read more
  • A Randomized Phase III Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
    Read more
  • A study of neurocognitive function in children treated for ALL
    Read more
  • Banking in Hodgkin Disease
    Read more
  • Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
    Read more
  • Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
    Read more
  • Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
    Read more
  • Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients.
    Read more
  • International Registry for Severe Chronic Neutropenia
    Read more
  • Key Adverse Events Following Childhood Cancer
    Read more
  • Neuroblastoma Biology Studies
    Read more
  • Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
    Read more
  • Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT): A Groupwide Phase II Study
    Read more
  • Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
    Read more
  • Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
    Read more
  • Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma
    Read more
  • Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
    Read more
  • Rare and Cutaneous Non-Hodgkin Lymphoma Registry
    Read more
  • Renal Tumors Classification, Biology and Banking Study
    Read more
  • Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
    Read more
  • Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor: A Groupwide Phase III Study
    Read more
  • Treatment of Children with All Stages of Hepatoblastoma
    Read more
  • Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL): A Groupwide Phase III Study
    Read more
  • Umbrella Long-Term Follow-Up Protocol
    Read more

Specialties & Certification

  • Pediatrics
  • Pediatric Hematology/Oncology

Diseases & Conditions Treated

  • Childhood Cancers

Treats

  • Children

Current Hospital Privileges

  • Upstate University Hospital

HealthLinkOnAir Radio Interview

2/20/13 Upstate receives St. Baldricks grant to benefit kids with cancer

Clinical Profile Shortcut: http://www.upstate.edu/findadoc/kerrk
Faculty Profile Shortcut: http://www.upstate.edu/faculty/kerrk

Practice/Contact Information

Center for Children's Cancer and Blood Disorders

Upstate University Hospital - Downtown Campus Maps and Directions
Address: UH 4A, 750 East Adams St., Syracuse, NY 13210
Phone: 315 464-5294
Fax: 315 464-7238
Website: Center for Children's Cancer and Blood Disorders
Insurance Info: Pediatric Service Group, LLP

Return to Previous Page

Return to Find a Doctor/Service